RespireRx Pharmaceuticals Inc (fka RSPI)

[gfp927z]

Haysaw, Hopefully Samyang will decide to convert, and Cortex can thus conserve the cash.

As I see it, from the current low stock price there should be big upside IF Cortex can get to the ADHD results (approx Q4-2011) and then ink an ADHD pharma deal. But reaching those goals will require raising more money.


Some potential nearer term catalysts for the stock include -


- IND acceptance by FDA (Psychiatric/Laughren), allowing the ADHD trial to start

- SA results - 'end of Summer' (figure Fall)

- ADHD trial starting in Q3

- Re-acquiring Schizo-Dep rights from Merck

- High Impacts related partnership